[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359644-105":59,"doc-detail-359644-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","planned-time-burden-for-patients-participating-in-phase-2-cancer-trials","Planned time burden for patients participating in phase 2 cancer trials","","Participation in cancer trials requires patients to spend time and carry research-related burden throughout study follow-up. This work extends prior findings from phase 1 settings by quantifying planned research days and associated clinic time in phase 2 cancer trial participation. Review of 73 phase 2 trial arms using posted protocols evaluates visit frequency, procedures, and the share of progression-free and overall survival time spent in clinic. Results show a median of 5 planned research days in the first 30 days and measurable time toxicity across the trial course.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/planned-time-burden-for-patients-participating-in-phase-2-cancer-trials/359644/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/planned-time-burden-for-patients-participating-in-phase-2-cancer-trials/359644.png","ImageObject",300,407,{"name":92,"@type":93},"Aria Callaghan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is “time toxicity” in the context of cancer trials?","Question",{"text":112,"@type":113},"Time toxicity is defined as time spent coordinating treatments and in visits to a healthcare facility, including travel, urgent/emergent care, hospitalizations, follow-up tests, and rehabilitation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How much time do patients typically spend on planned research days in phase 2 trials?",{"text":117,"@type":113},"In the first 30 days, patients have a median of 5 planned research days, and after that they have a median of 2 planned research days per month.",{"name":119,"@type":110,"acceptedAnswer":120},"How do planned research days relate to progression-free survival and overall survival time?",{"text":121,"@type":113},"Planned research days account for 10.5% of median progression-free survival time and 4.0% of median overall survival time.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},359644,1790465738,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Planned time burden for patients participating in phase 2 cancer trials  \nCharlotte Ouimet, MSc1, , Renata Iskander, PhD1, Ryan Nipp, MD, MPH, MBA2, ,  \nJonathan Kimmelman, PhD*,1,   \n1 Department of Equity, Ethics and Policy, McGill University School of Population and Global Health, Montreal, QC H3A 1G1, Canada 2 University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, OK 73104, United States  \n*Corresponding author: Department of Equity, Ethics and Policy, McGill University School of Population and Global Health, 2001 McGill College Avenue, Montreal, QC H3A 1G1, Canada ([jonathan.kimmelman@mcgill.ca](jonathan.kimmelman@mcgill.ca)) .  \nAbstract  \nBackground: Participation in cancer trials requires a commitment of time and research burden from patients. Prior work has highlighted the time burden of clinic visits during phase 1 trial participation. We extended these findings to phase 2 cancer trials.  \nMaterials and methods: We reviewed a random sample of 73 phase 2 cancer trial arms with results posted on [ClinicalTrials.gov](ClinicalTrials.gov) 2023-2024. We extracted scheduled visit frequency and procedures from each protocol. Primary outcomes included the absolute number of planned research days (PRDs) in the first 30 days and subsequent months of participation. Secondary outcomes included procedure volume throughout the trial. We also estimated the proportion of progression-free survival (PFS) and overall survival (OS) spent in clinic.  \nResults: The median number of PRDs in the first 30 days of participating in a phase 2 trial was 5 (IQR 4-7) and 2 (IQR 1-3) per month thereafter. Across the course of a trial, patients had a median of 13 PRDs and underwent a median of 13 (IQR 10-22) blood draws, 6 (IQR 2-26) infusions, and 1 (IQR 0-2) mandatory biopsy. PRDs accounted for 10.5% of median PFSand 4.0% of median OS. The average phase 2 trial involved a cumulative 11 patient-months of planned visits.  \nConclusion: Patients in phase 2 cancer trials commit a substantial amount of time to research participation. Further work is needed to compare these estimates to time spent in standard of care and to find ways to reduce the time toxicity of trial participation.  \nKey words: time toxicity; time burdens; phase 2 clinical trials; patient preference  \nImplications for Practice  \nMany patients with advanced cancer participate in phase 2 cancer trials seeking new treatment options. Yet such participation involves extra clinic visits, which patients sometimes experience as a burden. In this first of a kind study, we find that patients spend a median of 5 days visiting clinics for planned appointments in the first month of participation. In total, clinic visits absorb 10.5% of their progression-free survival time. Clinicians can use this information to help patients decide whether the time investments of trial participation align with their care goals.  \nIntroduction  \nParticipation in clinical trials often involves research procedureburdens. Beyond the physical risks of receiving experimental treatment, patients often attend extra clinic visits, submit to additional blood draws, and give tissue biopsies. Research visits  \ngenerally require longer stays and greater travel than standard care.1 Both the greater research burden and travel are especially the case for early-phase cancer trials.2,3 This cumulative burden of receiving treatment, whether in care or in a trial, has been called “time toxicity,” defined as “time spent coordinating treatments and in visits to a healthcare facility (including travel and  \nReceived: September 16, 2025. Accepted: March 9, 2026 © The Author(s) 2026. Published by Oxford University Press.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)), which permits noncommercial re-use, distribution, and reproduction in ","cbCaiqOUwieSoxcG","https://ap.wps.com/l/cbCaiqOUwieSoxcG","pdf",944939,"English","# Abstract\n## Background\n## Materials and methods\n## Results\n## Conclusion\n# Introduction\n## Time toxicity and trial participation\n## Phase 2 trial context and prior evidence\n# Implications for Practice","[{\"question\":\"What is “time toxicity” in the context of cancer trials?\",\"answer\":\"Time toxicity is defined as time spent coordinating treatments and in visits to a healthcare facility, including travel, urgent/emergent care, hospitalizations, follow-up tests, and rehabilitation.\"},{\"question\":\"How much time do patients typically spend on planned research days in phase 2 trials?\",\"answer\":\"In the first 30 days, patients have a median of 5 planned research days, and after that they have a median of 2 planned research days per month.\"},{\"question\":\"How do planned research days relate to progression-free survival and overall survival time?\",\"answer\":\"Planned research days account for 10.5% of median progression-free survival time and 4.0% of median overall survival time.\"}]","Planned time burden for patients participating in phase 2 cancer trials | PDF",1790137366,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/332e6a439f725bf6cfa9f0816a15aad9.webp",983,1291,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f66691a93300f751af6a20f321e5fb1a.webp",982,1290,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a451f1b6949e09d8c6d76726e5c9d509.webp",981,1289,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4a36174dd1fa2347b2af6a959c9430f.webp",980,1287]